discovery of hepatitis b virus capsid assembly inhibitors leading to a heteroaryldihydropyrimidine based clinical candidate (gls4):(发现乙肝病毒衣壳组装抑制剂导致heteroaryldihydropyrimidine基础临床候选人(gls4)).pdfVIP

discovery of hepatitis b virus capsid assembly inhibitors leading to a heteroaryldihydropyrimidine based clinical candidate (gls4):(发现乙肝病毒衣壳组装抑制剂导致heteroaryldihydropyrimidine基础临床候选人(gls4)).pdf

  1. 1、原创力文档(book118)网站文档一经付费(服务费),不意味着购买了该文档的版权,仅供个人/单位学习、研究之用,不得用于商业用途,未经授权,严禁复制、发行、汇编、翻译或者网络传播等,侵权必究。。
  2. 2、本站所有内容均由合作方或网友上传,本站不对文档的完整性、权威性及其观点立场正确性做任何保证或承诺!文档内容仅供研究参考,付费前请自行鉴别。如您付费,意味着您自己接受本站规则且自行承担风险,本站不退款、不进行额外附加服务;查看《如何避免下载的几个坑》。如果您已付费下载过本站文档,您可以点击 这里二次下载
  3. 3、如文档侵犯商业秘密、侵犯著作权、侵犯人身权等,请点击“版权申诉”(推荐),也可以打举报电话:400-050-0827(电话支持时间:9:00-18:30)。
  4. 4、该文档为VIP文档,如果想要下载,成为VIP会员后,下载免费。
  5. 5、成为VIP后,下载本文档将扣除1次下载权益。下载后,不支持退款、换文档。如有疑问请联系我们
  6. 6、成为VIP后,您将拥有八大权益,权益包括:VIP文档下载权益、阅读免打扰、文档格式转换、高级专利检索、专属身份标志、高级客服、多端互通、版权登记。
  7. 7、VIP文档为合作方或网友上传,每下载1次, 网站将根据用户上传文档的质量评分、类型等,对文档贡献者给予高额补贴、流量扶持。如果你也想贡献VIP文档。上传文档
查看更多
discovery of hepatitis b virus capsid assembly inhibitors leading to a heteroaryldihydropyrimidine based clinical candidate (gls4):(发现乙肝病毒衣壳组装抑制剂导致heteroaryldihydropyrimidine基础临床候选人(gls4))

Bioorganic Medicinal Chemistry 25 (2017) 1042–1056 Contents lists available at ScienceDirect Bioorganic Medicinal Chemistry journal homepage: www.else /locate/bmc Discovery of hepatitis B virus capsid assembly inhibitors leading to a heteroaryldihydropyrimidine based clinical candidate (GLS4) Qingyun Ren a,b, Xinchang Liu a,b, Zhonghua Luo a, Jing Li a, Chaolei Wang a,b, Siegfried Goldmann a,⇑, Jiancun Zhang c, Yingjun Zhang a,⇑ a Sunshine Lake Pharma Co., Ltd, Dong Guan 523808, China b Anti-infection Innovation Department, New Drug Research Institute, HEC Pharma Group, Dong Guan 523871, China c Guangzhou Institute of Biomedicine and Health, Chinese Academy of Sciences, Guangzhou 510530, China a r t i c l e i n f o a b s t r a c t Article history: Inhibition of hepatitis B virus (HBV) capsid assembly is a novel strategy for the development of chronic Received 16 November 2016 hepatitis B (CHB) therapeutics. Herein we described our lead optimization studies including the synthe- Accepted 10 December 2016 sis, molecular docking studies and structure-activity relationship (SAR) studies of a series of novel Available online 19 December 2016 heteroaryldihydropyrimidine (HAP) inhibitors of HBV capsid assembly inhibitors, and the discovery of a potent inhibitor of HBV capsid assembly of GLS4 (ethyl 4-[2-bromo-4-fluorophenyl]-6-[morpholino- Keywords: methyl]-2-[2-thiazolyl]-1,4-dihydro-pyrimidine-5-carboxylate) which is now in

您可能关注的文档

文档评论(0)

18273502 + 关注
实名认证
文档贡献者

该用户很懒,什么也没介绍

1亿VIP精品文档

相关文档